Expression Profile of Micrornas (106b-3p, 130b-3, 145-3p and 199a-5p) in Urine and Serum Samples From Patients With the Diagnosis of Bladder Cancer

Abstract

Background MicroRNAs (miRNA) are short, single stranded, non-coding RNAs that play an important role in controlling gene expression at the post-transcriptional stage. There is no bladder cancer marker that has been approved as an alternative for diagnostic cystoscopy and urine cytology so far, thus research for alternative, more sensitive, and less invasive methods of bladder cancer detection are being made. The aim of the study was to compare the relative expression levels of miRNAs in patients with bladder cancer.Materials and methods Urine and serum samples were collected from patients with the diagnosis of bladder cancer (NMIBC 71%, MIBC 29%). We assessed expression of 4 miRNAs (106b-3p, 130b-3, 145-3p and 199a-5p) using real-time PCR and double delta (ΔΔCt) method. The analysis was performed with the Mann-Whitney U test. Results miRNA 145-3p was significantly underexpressed in urine (p=0,0111) comparing with control group, whereas in serum we did not find relevant differences between groups (p=0,0903). Overexpression was observed for miRNA 199a-5p tested in urine (p=0,0262) and for miRNA 106b-3p for both urine and serum (p=0,0262 and p=0,0149 respectively) . For miR-130b-3 we did not find statistically significant differences neither for urine (p=0,6335) nor serum (p=0,2443).Conclusions A correlation between the relative levels of expression for miRNA 106b-3p, 199a-5p and miRNA 145-3p was detected. We also observed differences between the results obtained for urine and serum. In the content of urinary cancers diagnosis urine seems to be more useful material than serum. We plan to continue our studies assessing expression levels of miRNA 106b-3.

Urine micro-RNA signature as a potential non-invasive diagnostic biomarker in bladder cancer

“…Zaravinos et al, (2012) have reported downregulation of miR-145 in BC tissue samples compared with neighboring normal urothelium and their results were supported by Avgeris et al, (2015) who aimed to evaluate the unexplored clinical potential of the urological cancer-related miR-145 in a total of 279 bladder tissue specimens were included in their study (133 BC, 107 adjacent normal and 39 healthy samples), they stated that the expression level of miR-145 was significantly decreased. Kutwin et al, (2021) collected urine and serum samples from patients with bladder cancer, they assessed the expression of 4 miRNAs (106b-3p, 130b-3, 145 and 199a-5p) using real-time PCR, the statistical analysis was performed with the Mann-Whitney U test which revealed that miRNA-145 was significantly under-expressed in urine (P=0.0111) compared with control group, whereas in serum, they did not find relevant differences between groups (P=0.0903).…”

Identification of a three-miRNA panel in serum for bladder cancer diagnosis by a diagnostic test

“…The miRNA screening based on serum is a convenient and widely applicable diagnostic method, especially noninvasive. A lot of studies have explored if the serum miRNAs serve as the diagnostic tool in BC ( 19 , 20 ). In our study, we paid more attention to BC detection and designed a three-stage study to evaluate the diagnostic performance of serum miRNAs in BC.…”